Is SPHRF or DIVO a better dividend investment in 2026?

SPHRF currently yields 606.06% with a 5% 5-year dividend growth rate. DIVO yields 6.49% with 5% growth. The better choice depends on your goal: SPHRF offers higher current income.

What is the dividend yield difference between SPHRF and DIVO?

SPHRF has a forward dividend yield of 606.06% ($2.00/share annually). DIVO yields 6.49% ($2.91/share annually). The yield gap is 599.57 percentage points.

Home › Compare › SPHRF vs DIVO

SPHRF vs DIVO: Dividend Comparison 2026

SPHRF yields 606.06% · DIVO yields 6.49%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 SPHRF wins by $280371.14M in total portfolio value

INVESTMENT

TIME HORIZON10 years

SPHRF

● Live price

606.06%

Share price

$0.33

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$280371.17M

Annual income

$211,667,981,687.60

Full SPHRF calculator →

DIVO

● Live price

6.49%

Share price

$44.85

Annual div

$2.91

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$30.7K

Annual income

$981.68

Full DIVO calculator →

Portfolio growth — SPHRF vs DIVO

📍 SPHRF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	SPHRF	DIVO
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, SPHRF + DIVO cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

SPHRF pays

DIVO pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

SPHRF

Annual income on $10K today (after 15% tax)

$51,515.15/yr

After 10yr DRIP, annual income (after tax)

$179,917,784,434.46/yr

DIVO

Annual income on $10K today (after 15% tax)

$552.00/yr

After 10yr DRIP, annual income (after tax)

$834.43/yr

At 15% tax rate, SPHRF beats the other by $179,917,783,600.03/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of SPHRF + DIVO for your $10,000?

SPHRF: 50%DIVO: 50%

100% DIVO50/50100% SPHRF

Portfolio after 10yr

$140185.60M

Annual income

$105,833,991,334.64/yr

Blended yield

75.50%

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

SPHRF buys

DIVO buys

No recent congressional trades found for SPHRF or DIVO in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricSPHRFDIVO

Forward yield	606.06% ✓	6.49%
Annual dividend / share	$2.00	$2.91 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$280371.17M ✓	$30.7K
Annual income after 10y	$211,667,981,687.60 ✓	$981.68
Total dividends collected	$274648.71M ✓	$8.2K
Payment frequency	quarterly	quarterly
Sector	Stock	ETF

Year-by-year: SPHRF vs DIVO ($10,000, DRIP)

Year	SPHRF Portfolio	SPHRF Income/yr	DIVO Portfolio	DIVO Income/yr	Gap
1← crossover	$71,306	$60,606.06	$11,349	$649.42	+$60.0K → SPHRF
2	$480,183	$403,885.93	$12,833	$688.83	+$467.4K → SPHRF
3	$3,055,680	$2,541,883.57	$14,459	$727.90	+$3.04M → SPHRF
4	$18,386,820	$15,117,242.14	$16,238	$766.49	+$18.37M → SPHRF
5	$104,687,331	$85,013,433.96	$18,179	$804.47	+$104.67M → SPHRF
6	$564,382,839	$452,367,394.46	$20,293	$841.71	+$564.36M → SPHRF
7	$2,883,114,581	$2,279,224,943.60	$22,591	$878.14	+$2883.09M → SPHRF
8	$13,966,501,456	$10,881,568,854.67	$25,087	$913.65	+$13966.48M → SPHRF
9	$64,208,586,900	$49,264,430,341.75	$27,791	$948.18	+$64208.56M → SPHRF
10	$280,371,169,670	$211,667,981,687.60	$30,718	$981.68	+$280371.14M → SPHRF

SPHRF vs DIVO: Complete Analysis 2026

SPHRF — Stock

Starpharma Holdings Limited, a biopharmaceutical company, engages in the research, development, and commercialization of dendrimer products for pharmaceutical, life-science, and other applications worldwide. It offers VivaGel, a non-antibiotic therapy for the treatment and prevention of bacterial vaginosis. The company also develops VivaGel condom, an antiviral condom; and VIRALEZE, an antiviral nasal spray. In addition, it develops DEP, a dendrimer drug delivery technology, including DEP docetaxel that is in Phase 2 clinical trials, DEP cabazitaxel that is in Phase 2 clinical trial, DEP gemcitabine that is in a Phase 1/2 clinical trials, and DEP irinotecan that is in Phase 2 clinical trials for the treatment of cancer; DEP radiotheranostics for cancer treatment and diagnosis; DEP Antibody Drug Conjugates; DEP HER-2 ADC; DEP non-oncology candidates; and DEP AZD0466, which is in Phase 1/2 clinical trials to treat haematological malignancies. The company was founded in 1996 and is headquartered in Abbotsford, Australia.

Full SPHRF Calculator →

DIVO — ETF

DIVO is an ETF of high-quality large cap companies with a history of dividend and earnings growth, along with a tactical covered call* strategy on individual stocks. DIVO is strategically designed to offer high levels of total return on a risk-adjusted basis.

Full DIVO Calculator →

📬

Get this SPHRF vs DIVO comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

SPHRF vs SCHD SPHRF vs JEPI SPHRF vs O SPHRF vs KO SPHRF vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.